ToGenx focuses on the innovation of key technologies for gene therapy, aiming to promote the rapid development of gene therapies and change the current situation of slow R&D relative to widespread market demand. In recent years, significant progress has been made in gene therapy, with 8 direct gene therapies available in the global market. Clearly, gene therapy is still in its early stages, urgently needing technological innovations to address numerous challenges, including viral vector manufacturing, tissue/cell targeting, and viral vector immunogenicity. These technical challenges have led to high costs for gene therapies, with a single treatment costing up to $4 million, severely limiting the practicality of gene therapies. ToGenx is advancing the industrialization of its innovative viral preparation technology system to solve the challenges of viral manufacturing for gene therapies. Ongoing innovations include the research and development of high-yield adeno-associated virus (AAV) technologies and the creation of cancer cell-specific AAV vectors. The creation of cancer cell-specific AAV vectors is an early step for ToGenx to pioneer a new approach to AAV cancer gene therapy.